These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 6448870)

  • 21. Changes in plasma levels of protease and fibrinolytic inhibitors induced by treatment in acute myeloid leukemia.
    Velasco F; Torres A; Andres P; Martinez F; Gomez P
    Thromb Haemost; 1984 Aug; 52(1):81-4. PubMed ID: 6238445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasminogen activators: pharmacology and therapy.
    Holden RW
    Radiology; 1990 Mar; 174(3 Pt 2):993-1001. PubMed ID: 2137641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alpha2-antiplasmin and its deficiency: fibrinolysis out of balance.
    Carpenter SL; Mathew P
    Haemophilia; 2008 Nov; 14(6):1250-4. PubMed ID: 19141165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levels of fibrinolytic activators and inhibitors in plasma after severe trauma.
    Sørensen JV
    Blood Coagul Fibrinolysis; 1994 Feb; 5(1):43-9. PubMed ID: 7514044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Influence of antiplasmin on fibrinolysis and fibrinogenolysis].
    Bratus' GM; Byshevskiĭ ASh
    Ukr Biokhim Zh; 1971; 43(2):178-82. PubMed ID: 4254692
    [No Abstract]   [Full Text] [Related]  

  • 26. Trinitrophenyl-derivative of urinary trypsin inhibitor: a strong antifibrinolytic agent.
    Sumi H; Hamada H; Maehara S; Yoshida E; Tsushima H; Maruyama M; Mihara H
    Acta Haematol; 1987; 78(4):225-8. PubMed ID: 2962413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome.
    Vaziri ND; Gonzales EC; Shayestehfar B; Barton CH
    J Lab Clin Med; 1994 Jul; 124(1):118-24. PubMed ID: 7518491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
    Collen D; Lijnen HR
    Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A study of hemostasis in ischemic cerebrovascular disease. III. Abnormalities in vascular plasminogen activators, antiactivators and alpha 2-antiplasmin.
    Mettinger KL; Egberg N
    Thromb Res; 1982 May; 26(3):203-10. PubMed ID: 6810498
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inter-alpha-antiplasmin: its distinction from antiactivator.
    Gallimore MJ
    Thromb Res; 1978 Apr; 12(4):687-92. PubMed ID: 149395
    [No Abstract]   [Full Text] [Related]  

  • 31. Fibrinolytic activity and protein C in preeclampsia.
    Aznar J; Gilabert J; Estellés A; España F
    Thromb Haemost; 1986 Jun; 55(3):314-7. PubMed ID: 3092388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular mechanism of fibrinolysis.
    Lijnen HR; Collen D
    Adv Exp Med Biol; 1984; 164():217-28. PubMed ID: 6421102
    [No Abstract]   [Full Text] [Related]  

  • 33. [Role of the initial level of plasminogen activator in changes in fibrinolysis].
    Andreenko GV; Liutova LV; Karabasova MA; Podorol'skaia LV; Serebriakova TN
    Fiziol Zh SSSR Im I M Sechenova; 1983 Mar; 69(3):380-5. PubMed ID: 6343132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Recent progress in fibrinolytic mechanism].
    Yasukouchi T
    Rinsho Byori; 1986 Mar; 34(3):235-46. PubMed ID: 3086600
    [No Abstract]   [Full Text] [Related]  

  • 35. Carbon monoxide releasing molecule-2 enhances α2-antiplasmin activity.
    Malayaman SN; Cohen JB; Machovec KA; Bernhardt BE; Arkebauer MR; Nielsen VG
    Blood Coagul Fibrinolysis; 2011 Jun; 22(4):345-8. PubMed ID: 21330914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Observations on fibrinolysis; plasminogen, plasmin, and antiplasmin content of human blood.
    MACFARLANE RG; PILLING J
    Lancet; 1946 Oct; 2(6425):562-5. PubMed ID: 21001709
    [No Abstract]   [Full Text] [Related]  

  • 38. Synthetic fibrinolytic agents.
    Davidson JF; Walker ID
    Prog Cardiovasc Dis; 1979; 21(5):375-96. PubMed ID: 154124
    [No Abstract]   [Full Text] [Related]  

  • 39. Immunochemical distinction between the inhibitors of plasminogen activation and antiplasmin in human plasma.
    Hender U; Collen D
    Thromb Res; 1976 Jun; 8(6):875-9. PubMed ID: 134465
    [No Abstract]   [Full Text] [Related]  

  • 40. Pathophysiology of fibrinolysis.
    Declerck PJ; Juhan-Vague I; Felez J; Wiman B
    J Intern Med; 1994 Oct; 236(4):425-32. PubMed ID: 7523565
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.